Sigilon Therapeutics names new director.
M2 EQUITYBITES-November 2, 2017-Sigilon Therapeutics names new director
(C)2017 M2 COMMUNICATIONS http://www.m2.com
Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, announced yesterday that it has named Eric Shaff as its new director.
Shaff is executive vice president and chief financial officer of Seres Therapeutics (NASDAQ: MCRB). Prior to Seres, he worked at Momenta Pharmaceuticals and Genzyme Corporation, where he served as global head of finance of Genzyme's Rare Genetic Disease Division, in addition to roles in corporate development and corporate finance. He has also worked in corporate finance at Pfizer and in investment banking with Broadview International (now Jefferies Broadview).
Douglas Cole, MD, chairman of Sigilon Therapeutics' board, said, 'Mr Shaff's experience in company building, finance, and corporate development, notably in emerging areas of biotechnology, will be particularly helpful as we develop a new Afibromer cell factory approach to the treatment of chronic diseases. We are pleased that Mr Shaff will share his perspectives and experience as a member of the board and appreciate his recognition of the promise of Sigilon's technology platform.'
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Nov 2, 2017|
|Previous Article:||Astellas promotes James Miteff and and Gregory Apostol.|
|Next Article:||Lemminkainen's EVP, Strategy and Development leaves.|